AR and posterior cortical atrophy: The findings of our study, in agreement with other experimental evidence [75,88,92], provide the rationale for testing the efficacy of epigenetic drugs in the treatment of PCa and Adeno-CRPC, as the molecular alterations observed in PCa evolution toward metastatic and resistant phenotypes mainly affect transcription factors and coregulators involved in AR activity (Figure 8, Tables S7 and S9).